HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cosmetics Stakeholders Race To Hitch Reform Provisions To FDA User-Fee Bills

This article was originally published in The Rose Sheet

Executive Summary

The Personal Care Products Council says consensus has nearly been reached between industry and consumer advocates on cosmetics reform provisions they hope to attach to FDA user-fee legislation. The groups must produce broadly supported, noncontroversial language by mid-March in order to have a shot at inclusion in the critical reauthorization bills, which typically pass well in advance of October deadlines.

You may also be interested in...



Cosmetics Provisions Unlikely To Catch Ride On FDA User-Fee Bill

With the release of an atypically lean, clean FDA user-fee reauthorization draft bill, it’s doubtful that cosmetics regulatory reform language will get tacked onto the must-pass legislation. Stakeholders likely will refocus their efforts on standalone cosmetics legislation to modernize FDA’s oversight of the industry.

Trump's Budget Blueprint: Cosmetics Opportunity Or Unhelpful Distraction?

President Trump appears to want greater user-fee contributions from FDA-regulated industries to offset cuts to federal spending in fiscal 2018. His recently released budget blueprint could complicate negotiations that cosmetics stakeholders were hoping to join, but it also could signal opportunity for an industry seeking increased regulation – and willing to pay for it.

PCPC Hatching Proposal For CIR Role In FDA Ingredient Review

The Personal Care Products Council has a vision for marrying the Cosmetic Ingredient Review’s expertise with FDA’s authority, which it hopes to package into reform legislation expected this year. While FDA has balked at formalizing CIR’s role under previous proposals, this one was inspired by a third-party review program for medical devices, making it potentially more palatable to the agency and lawmakers.

Related Content

Topics

UsernamePublicRestriction

Register

RS109117

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel